Please use this identifier to cite or link to this item: https://hdl.handle.net/1822/74140

TitleAdipoSIGHT in therapeutic response: consequences in osteosarcoma treatment
Author(s)Kundu, Banani
Brancato, Virginia
Oliveira, Joaquim
Correlo, V. M.
Reis, R. L.
Kundu, Subhas C
KeywordsHeterotypic tumorspheres
Nonadherent surface
Osteosarcoma
Human adipose-derived stem cells
Drug response
Issue date10-Jun-2021
PublisherMultidisciplinary Digital Publishing Institute (MDPI)
JournalBioengineering
CitationKundu, B.; Brancato, V.; Oliveira, J.; Correlo, V..; Reis, R..; Kundu, S. C. adipoSIGHT in Therapeutic Response: Consequences in Osteosarcoma Treatment. Bioengineering 2021, 8, 83. https://doi.org/10.3390/bioengineering8060083
Abstract(s)Chemotherapeutic resistance is a major problem in effective cancer treatment. Cancer cells engage various cells or mechanisms to resist anti-cancer therapeutics, which results in metastasis and the recurrence of disease. Considering the cellular heterogeneity of cancer stroma, the involvement of stem cells is reported to affect the proliferation and metastasis of osteosarcoma. Hence, the duo (osteosarcoma: Saos 2 and human adipose-derived stem cells: ASCs) is co-cultured in present study to investigate the therapeutic response using a nonadherent, concave surface. Staining with a cell tracker allows real-time microscopic monitoring of the cell arrangement within the sphere. Cell–cell interaction is investigated by means of E-cadherin expression. Comparatively high expression of E-cadherin and compact organization is observed in heterotypic tumorspheres (Saos 2–ASCs) compared to homotypic ones (ASCs), limiting the infiltration of chemotherapeutic compound doxorubicin into the heterotypic tumorsphere, which in turn protects cells from the toxic effect of the chemotherapeutic. In addition, genes known to be associated with drug resistance, such as SOX2, OCT4, and CD44 are overexpressed in heterotypic tumorspheres post-chemotherapy, indicating that the duo collectively repels the effect of doxorubicin. The interaction between ASCs and Saos 2 in the present study points toward the growing oncological risk of using ASC-based regenerative therapy in cancer patients and warrants further investigation.
TypeArticle
URIhttps://hdl.handle.net/1822/74140
DOI10.3390/bioengineering8060083
ISSN2306-5354
Publisher versionhttps://www.mdpi.com/2306-5354/8/6/83
Peer-Reviewedyes
AccessOpen access
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
bioengineering-08-00083.pdf3,73 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID